Filing Details

Accession Number:
0001140361-14-008923
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-20 21:37:33
Reporting Period:
2014-02-18
Filing Date:
2014-02-20
Accepted Time:
2014-02-20 21:37:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070698 Raptor Pharmaceutical Corp RPTP Pharmaceutical Preparations (2834) 860883978
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1235470 M Christopher Starr C/O Raptor Pharmaceutical Corp.
5 Hamilton Landing, Suite 160
Novato CA 94949
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-18 15,000 $2.97 714,370 No 4 M Direct
Common Stock Acquisiton 2014-02-18 10,000 $3.54 724,370 No 4 M Direct
Common Stock Disposition 2014-02-18 25,000 $15.26 699,370 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock options (right to buy) Disposition 2014-02-18 15,000 $0.00 15,000 $2.97
Common Stock Stock options (right to buy) Disposition 2014-02-18 10,000 $0.00 10,000 $3.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
134,289 2020-10-11 No 4 M Direct
295,054 2020-11-21 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 13, 2013.
  2. Fully vested and exercisable.
  3. Stock options vest starting on September 1, 2010, 6/48ths on February 28, 2011 and 1/48th per month thereafter.
  4. This transaction was executed in multiple trades at prices ranging from $15.01 to $15.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. The shares listed as owned in column 9 represents the total shares outstanding for this option grant. The previous report reported only a portion of the grant which should have consisted of both the ISO and NQSO shares granted pursuant to the ISO $100,000 limitation rule. This total now reflects the total options outstanding under this grant. No changes have been made to the original options granted.